mTOR Inhibitors
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells
... with inhibitors of the phosphoi- nositide 3-kinase/AKT/mammalian target of rapamycin (PI3K/AKT/mTOR) ...PI3K/mTOR inhibitors are under evaluation in numerous clinical trials ...
12
The efficacy and adverse events of mTOR inhibitors in lymphangioleiomyomatosis: systematic review and meta-analysis
... Hopefully, mTOR inhibitors have shown the significant therapeutic effects on the regression of angiomyolipoma volume and the partial improvement or stabilization on the lung function in TSC or LAM patients ...
8
Optimizing immunosuppression with mTOR inhibitors in renal transplant recipients
... calcineurin inhibitors (CNIs) cyclosporine and later on tacrolimus came available to the ...calcineurin inhibitors are also associated with severe toxicity such as acute and chronic nephrotoxicity ...
257
mTOR inhibitors effects on regulatory T cells and on dendritic cells
... mTOR inhibitors. Nevertheless, after 10 years of clinical experience mTOR inhibitors are still far to be positioned as a first-line immunosuppression in organ ...of mTOR ...
9
A subset of diffuse-type gastric cancer is susceptible to mTOR inhibitors and checkpoint inhibitors
... In the present study, we established PDX lines from diffuse-type GCs, and found that the features of diffuse-type and mixed-type GC-initiating cells were dif- ferent from those of intestinal-type cells. We also found ...
23
Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy
... another mTOR inhib- itor, temsirolimus, the most common adverse events of all grades observed in everolimus-treated patients included fatigue, stomatitis, rash, nausea, anorexia, and ...classic mTOR ...
12
The effect of mTOR inhibitors on respiratory infections in lymphangioleiomyomatosis
... which mTOR inhibitors may prevent respiratory infection is ...with mTOR inhibitors may indirectly help restore or normalise the pulmonary microbiome ...by mTOR inhibitors, airway ...
7
Hyperglycemia and Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management.
... Clinical characteristics including clinical, laboratory, deomographic data (personal and family history of diabetes, steroid use, body mass index, baseline blood sugar, biochemistiry), and outcomes of patients treated ...
20
Mutant HRAS as novel target for MEK and mTOR inhibitors
... and mTOR inhibitors was previously observed in HRAS wild-type lung cancer cell lines ...down-stream mTOR complex could be an effective target for mutant ...available mTOR inhibitor Everolimus ...
14
Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis
... of mTOR inhibitors associated with TSC therapy include stomatitis, upper respiratory tract infections, and nasopharyngitis except cough, vomiting and ...received mTOR inhib- itors had a higher risk ...
9
mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib
... Potent inhibitors of BRAFV600E, such as vemurafenib, show great promise for treatment of BRAFV600E-positive thyroid ...checkpoint inhibitors combined with targeted therapy are also being considered in ...
12
Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma
... ALK inhibitors with an mTOR inhibitor (temsirolimus), in ALK+ lymphoma ...of mTOR effectors, compared to single treatments, a block in G0/G1 phase and induction of ...and mTOR ...
12
Targeting carbonic anhydrase IX improves the anti-cancer efficacy of mTOR inhibitors
... Most tumors are characterized by regions of hypoxia that contribute to chemo- and radioresistance [9]. Our findings show that hypoxia also contributes to resistance to mTOR inhibitors. Indeed, we outline ...
15
Clinical development of mTOR inhibitors in breast cancer
... described. mTOR acti- vation was shown to mediate resistance to endocrine therapy in preclinical models ...Furthermore, mTOR inhibitors such as everolimus synergized with letrozole in preclinical ...
9
Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy
... Many of these patients had slow progression over many years despite recurrences, and the question is when to initiate treatment? Both cases showed demonstrable clinical benefit and tumour shrinkage with frequent ...
6
Rapalogs and mTOR inhibitors as anti aging therapeutics
... and mTOR inhi- bition to longevity were performed in organisms that are mainly postmitotic (worms and flies) or single celled (yeast) and therefore do not experience ...
11
Design, Synthesis, Characterization and Pharmacological Evaluation of mTOR Inhibitors for Anticancer Activity.
... Review related to modeling of target protein for drug design: Karunakar tanneeru et.al, 24 2011 Ligand-based 3-D pharmacophore generation and molecular docking of mTOR kinase inhibitors.[r] ...
108
The mTOR kinase inhibitors polarize glioma-activated microglia to express a M1 phenotype
... ATP-competitive mTOR inhibitors have been developed, which block both mTORC1 and mTORC2 ...between mTOR and PI3K, some compounds originally identified as PI3K inhibitors were later shown to ...
10
Akt and mTOR mediate programmed necrosis in neurons
... and mTOR mediate programmed necrosis in neuronal ...and mTOR. Herein, we report activation of Akt/mTOR signaling pathways and neuronal cell death that are inhibited by pharmacologic or genetic ...
11
Bailey_unc_0153D_14876.pdf
... catalytic mTOR inhibitors have been shown to improve efficacy over allosteric mTOR inhibitors in RCC [94,96] there too are consequences of such ...catalytic mTOR inhibitors have ...
105